BioCentury | Nov 8, 2010
Finance

Wanted: Less Dilution

...$1.8 8 $185.4 Xcelience Holdings LLC $1.8 14 ND Omeros Corp. (NASDAQ:OMER) $1.7 8 $131.2 ImQuest...
BioCentury | Apr 13, 2009
Clinical News

ImQuest preclinical data

...from Samjin Pharmaceutical Co. Ltd. (Seoul, South Korea) in 2006 (see BioCentury, March 6, 2006). ImQuest...
BioCentury | Apr 13, 2009
Clinical News

ImQuest preclinical data

...from Samjin Pharmaceutical Co. Ltd. (Seoul, South Korea) in 2006 (see BioCentury, March 6, 2006). ImQuest...
BioCentury | Apr 13, 2009
Clinical News

ImQuest preclinical data

...inhibitor of microtubule polymerization. Data were presented at the Targeted Cancer Therapeutics meeting in Whistler. ImQuest...
BioCentury | Feb 16, 2009
Clinical News

ImQuest preclinical data

...and HIV-2. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Montreal. ImQuest...
BioCentury | Jan 12, 2009
Clinical News

IQP-0410: Phase I start

...This quarter, ImQuest will begin a dose-escalation, U.S. Phase I trial to evaluate oral IQP-0410 in...
...begin a dose-escalation, U.S. Phase I trial to evaluate oral IQP-0410 in 24 healthy volunteers. ImQuest...
BioCentury | Jan 5, 2009
Clinical News

ImQuest Pharmaceuticals Inc. preclinical data

...reverse transcriptase inhibitors (NNRTIs). IQP-0410 is expected to enter Phase I trials in early 2009. ImQuest...
BioCentury | Aug 11, 2008
Company News

ImQuest Pharmaceuticals Inc., Duke University, Miriam Hospital at Brown University, National Institutes of Health, University of Pittsburgh, University of Utah

...topical microbicide to prevent HIV transmission. The company will work with the universities to develop ImQuest’s...
...ISIS 5320, and thioesters that target HIV nucleocapsid p7 (NCp7). Further details were not disclosed. ImQuest...
...prevents the interaction of gp120 with CD4 on target cells had completed Phase I trials. ImQuest...
BioCentury | Jun 5, 2006
Finance

Isis chronicles

...Symphony GenIsis , which was formed by merchant bank Symphony Capital Q. 4/18/06 - Grants ImQuest...
BioCentury | May 1, 2006
Company News

ImQuest, Samjin Pharmaceutical Co. Ltd. deal

...microtubule synthesis and cell cycle inhibitors. Samjin will retain rights to the compounds in Korea. ImQuest...
Items per page:
1 - 10 of 14
BioCentury | Nov 8, 2010
Finance

Wanted: Less Dilution

...$1.8 8 $185.4 Xcelience Holdings LLC $1.8 14 ND Omeros Corp. (NASDAQ:OMER) $1.7 8 $131.2 ImQuest...
BioCentury | Apr 13, 2009
Clinical News

ImQuest preclinical data

...from Samjin Pharmaceutical Co. Ltd. (Seoul, South Korea) in 2006 (see BioCentury, March 6, 2006). ImQuest...
BioCentury | Apr 13, 2009
Clinical News

ImQuest preclinical data

...from Samjin Pharmaceutical Co. Ltd. (Seoul, South Korea) in 2006 (see BioCentury, March 6, 2006). ImQuest...
BioCentury | Apr 13, 2009
Clinical News

ImQuest preclinical data

...inhibitor of microtubule polymerization. Data were presented at the Targeted Cancer Therapeutics meeting in Whistler. ImQuest...
BioCentury | Feb 16, 2009
Clinical News

ImQuest preclinical data

...and HIV-2. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Montreal. ImQuest...
BioCentury | Jan 12, 2009
Clinical News

IQP-0410: Phase I start

...This quarter, ImQuest will begin a dose-escalation, U.S. Phase I trial to evaluate oral IQP-0410 in...
...begin a dose-escalation, U.S. Phase I trial to evaluate oral IQP-0410 in 24 healthy volunteers. ImQuest...
BioCentury | Jan 5, 2009
Clinical News

ImQuest Pharmaceuticals Inc. preclinical data

...reverse transcriptase inhibitors (NNRTIs). IQP-0410 is expected to enter Phase I trials in early 2009. ImQuest...
BioCentury | Aug 11, 2008
Company News

ImQuest Pharmaceuticals Inc., Duke University, Miriam Hospital at Brown University, National Institutes of Health, University of Pittsburgh, University of Utah

...topical microbicide to prevent HIV transmission. The company will work with the universities to develop ImQuest’s...
...ISIS 5320, and thioesters that target HIV nucleocapsid p7 (NCp7). Further details were not disclosed. ImQuest...
...prevents the interaction of gp120 with CD4 on target cells had completed Phase I trials. ImQuest...
BioCentury | Jun 5, 2006
Finance

Isis chronicles

...Symphony GenIsis , which was formed by merchant bank Symphony Capital Q. 4/18/06 - Grants ImQuest...
BioCentury | May 1, 2006
Company News

ImQuest, Samjin Pharmaceutical Co. Ltd. deal

...microtubule synthesis and cell cycle inhibitors. Samjin will retain rights to the compounds in Korea. ImQuest...
Items per page:
1 - 10 of 14